Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug

Marina Vivarelli; Francesco Emma

doi:10.1016/j.kint.2018.10.008

Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug

Kidney Int. 2019 Jan;95(1):25-28. doi: 10.1016/j.kint.2018.10.008.

Authors

Marina Vivarelli¹, Francesco Emma²

Affiliations

¹ Division of Nephrology, Department of Pediatric Subspecialties, Bambino Gesù Children's Hospital IRCCS, Rome, Italy. Electronic address: [email protected].
² Division of Nephrology, Department of Pediatric Subspecialties, Bambino Gesù Children's Hospital IRCCS, Rome, Italy. Electronic address: [email protected].

PMID: 30606425
DOI: 10.1016/j.kint.2018.10.008

Abstract

In the current issue of Kidney International, Sinha et al. report results of a randomized controlled trial comparing levamisole and mycophenolate mofetil for the second-line treatment of children with frequent relapses of nephrotic syndrome. This study suggests that these two agents may both be safe and effective. The present commentary addresses strengths and limitations of this important study.

Publication types

Comment

MeSH terms

Child
Glucocorticoids
Humans
Immunosuppressive Agents
Levamisole
Mycophenolic Acid*
Nephrotic Syndrome*
Recurrence

Substances

Glucocorticoids
Immunosuppressive Agents
Levamisole
Mycophenolic Acid